All Articles

A new partnership between Japan's Ono Pharma and US biotech Mediar aims to disrupt the massive fibro-inflammatory disease market by targeting the root cell of scarring.

The payment tech firm posts record cash flow and raises guidance, but a closer look reveals a story of strategic acquisitions and uneven performance.

BKV Corp. is building a new energy model, using robust gas profits to fund an ambitious expansion into power generation and carbon capture technology.

The utility's strong Q2 results are fueled by massive energy demand from new data centers, prompting a $1B capital plan increase and promising regional growth.

A shocking $31M loss forces ethical egg purveyor Vital Farms into a defensive crouch, testing if brand loyalty can survive a brutal market oversupply.

A new government initiative is accelerating a massive Québec phosphate mine, revealing a strategy to secure vital resources for food and batteries.

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

Sotera Health posted stellar Q2 results and raised its 2026 outlook, but a closer look at the numbers reveals a company navigating complex EO litigation.

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

With a return to profitability and digital revenue soaring, Lee Enterprises' Q3 results reveal a potent mix of financial strategy and digital transformation.

A new federal grant is helping Frontier Lithium turn mining by-products into valuable fertilizer, a key step in building a greener North American battery supply chain.

Genius Sports raises its outlook on soaring revenue post-acquisition, but a deeper look reveals widening losses. Can its strategic bet on data and media pay off?

With a strong cash runway to 2028 and key data expected, Aclaris is advancing a multi-asset portfolio against complex immuno-inflammatory diseases.

Bob's Discount Furniture's impressive Q2 earnings reveal a dual victory: a value proposition resonating with cautious consumers and a massive tariff refund.

Veritas Capital's acquisition of Saber Power isn't just a deal; it's a high-stakes play on the infrastructure backbone of the AI and data center boom.

Solid growth and a key FDA approval showcase Kenvue's value as it barrels toward a transformative merger, creating a new consumer health powerhouse.

Lithium Americas secures crucial financing for its Nevada mega-project, a move to navigate peak construction costs and reinforce its role in U.S. EV independence.

Despite a reported loss, DNOW's record cash flow, aggressive buybacks, and operational wins signal a powerful turnaround. Is this the new blueprint for resilience?

Playtika's Q2 results reveal a strategic pivot. Soaring revenue and DTC growth mask a drop in paying users, signaling a disciplined focus on profit over scale.

Heartland Dental CEO Pat Bauer's Titan Award celebrates his 'doctor-led' vision. But what does this mean for an industry increasingly shaped by private equity?